AZN vs. MDGL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and MDGL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, MDGL is a standard domestic listing.
| Symbol | AZN | MDGL |
|---|---|---|
| Company Name | AstraZeneca PLC | Madrigal Pharmaceuticals, Inc. |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 249.69 billion USD | 8.73 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | May 12, 1993 | February 6, 2007 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of AZN and MDGL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AZN | MDGL |
|---|---|---|
| 5-Day Price Return | 2.95% | 5.46% |
| 13-Week Price Return | 12.30% | 34.72% |
| 26-Week Price Return | 0.63% | 11.36% |
| 52-Week Price Return | -9.49% | 52.56% |
| Month-to-Date Return | 4.04% | 29.47% |
| Year-to-Date Return | 12.55% | 26.93% |
| 10-Day Avg. Volume | 1.07M | 0.45M |
| 3-Month Avg. Volume | 1.56M | 0.37M |
| 3-Month Volatility | 22.19% | 48.92% |
| Beta | 0.98 | -1.10 |
Profitability
Return on Equity (TTM)
AZN
19.84%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
MDGL
-38.38%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MDGL has a negative Return on Equity of -38.38%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
AZN
14.68%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
MDGL
-54.68%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MDGL has a negative Net Profit Margin of -54.68%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
AZN
20.04%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
MDGL
-60.09%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MDGL has a negative Operating Profit Margin of -60.09%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | AZN | MDGL |
|---|---|---|
| Return on Equity (TTM) | 19.84% | -38.38% |
| Return on Assets (TTM) | 7.76% | -27.32% |
| Net Profit Margin (TTM) | 14.68% | -54.68% |
| Operating Profit Margin (TTM) | 20.04% | -60.09% |
| Gross Profit Margin (TTM) | 82.07% | 96.28% |
Financial Strength
Current Ratio (MRQ)
AZN
0.86
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MDGL
5.11
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MDGL’s Current Ratio of 5.11 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
AZN
0.73
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MDGL
0.17
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MDGL’s Debt-to-Equity Ratio of 0.17 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
AZN
9.51
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
MDGL
-163.11
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
MDGL has a negative Interest Coverage Ratio of -163.11. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | AZN | MDGL |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 5.11 |
| Quick Ratio (MRQ) | 0.67 | 4.48 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 0.17 |
| Interest Coverage Ratio (TTM) | 9.51 | -163.11 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AZN
2.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
AZN’s Dividend Yield of 2.00% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
AZN
59.51%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MDGL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | AZN | MDGL |
|---|---|---|
| Dividend Yield (TTM) | 2.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 59.51% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
AZN
29.72
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
A P/E Ratio of 29.72 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
MDGL
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MDGL is currently unavailable.
Price-to-Sales Ratio (TTM)
AZN
4.36
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
AZN’s P/S Ratio of 4.36 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MDGL
16.97
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
MDGL’s P/S Ratio of 16.97 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
AZN
4.74
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
AZN’s P/B Ratio of 4.74 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MDGL
9.65
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MDGL’s P/B Ratio of 9.65 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | AZN | MDGL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.72 | -- |
| Price-to-Sales Ratio (TTM) | 4.36 | 16.97 |
| Price-to-Book Ratio (MRQ) | 4.74 | 9.65 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.13 | 253.68 |